Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy  ± immune checkpoint inhibition

CONCLUSION: In stage III NSCLC, smaller rMTV is highly associated with superior clinical outcome, especially in patients undergoing CRT without ICI. Patients with CRT-IO show significantly improved outcome compared to CRT patients. Of note, clinical outcome in CRT-IO patients is independent of residual MTV. Hence, even patients with large rMTV might profit from ICI despite extensive tumor load.PMID:34664091 | DOI:10.1007/s00259-021-05584-w

Source: Molecular Medicine - October 19, 2021 Category: Molecular Biology Authors: Marcus Unterrainer Julian Taugner Lukas K äsmann Amanda Tufman Niels Reinmuth Minglun Li Lena M Mittlmeier Peter Bartenstein Wolfgang G Kunz Jens Ricke Claus Belka Chukwuka Eze Farkhad Manapov Source Type: research